Table 2 Descriptive characteristics of the primary study cohort. MRI positive data is shown as the PI-RADS score of ≥ 3 or ≥ 4. Detection rates for cancer are shown for any cancer, and using definitions of ≥ Grade Group 2 (GG2 or ≥ Cambridge Prognostic Group 3 [CPG3]
|  | ≥ GG2 cancer detection | pvalue (vs. PSA) | ≥ CPG3 cancer detection | pvalue (vs.PSA) |
|---|---|---|---|---|
Whole cohort | ||||
PSA | 0.70 (0.66–0.74) | – | 0.81 (0.78–0.85) | – |
PSAd | 0.79 (0.75–0.83) | < 0.001 | 0.84 (0.80–0.87) | 0.12 |
phi | 0.82 (0.78–0.85) | < 0.001 | 0.87 (0.84–0.90) | < 0.001 |
MRI | 0.63 (0.59–0.66) | < 0.001* | 0.63 (0.60–0.66) | < 0.001* |
MRI + PSA | 0.76 (0.72–0.80) | < 0.001 | 0.85 (0.81–0.88) | 0.03 |
MRI + PSAd | 0.81 (0.77–0.84) | < 0.001 | 0.85 (0.81–0.88) | 0.08 |
MRI + phi | 0.81 (0.78–0.85) | < 0.001 | 0.86 (0.83–0.90) | 0.02 |
MRI negative | ||||
PSA | 0.64 (0.52–0.76) | – | 0.86 (0.76–0.97) | – |
PSAd | 0.76 (0.64–0.87) | 0.01 | 0.95 (0.91–0.99) | 0.08 |
phi | 0.78 (0.66–0.90) | 0.01 | 0.89 (0.74–1.00) | 0.76 |